FDA and Global Regulators Accelerate AI Adoption in Life Sciences for 2026

Summary

Pharmaphorum reports that 2026 will mark a pivotal shift in biopharma's AI adoption, moving from pilot programs to enterprise-scale deployment as regulators like the FDA formalize frameworks for agentic AI in life sciences. The FDA's definition of agentic AI — systems that achieve specific goals through autonomous reasoning with built-in guidelines and human oversight — is setting a new operating standard for the industry. Sponsors are scaling AI programs across regulatory, medical-writing, and